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Abstract
Background & Aims: Appearance of auto antibodies have been described 
during anti-tumor necrosis factor (TNF) alpha therapy; however, their prevalence and 
clinical relevance are still unclear. We investigated prevalence of autoantibo dies in 
inflammatory bowel diseases (IBD) patients on anti-TNFα treatment and occurrence of 
clinical symptoms. 
Methods: Titers of ANA, anti-dsDNA, SMA, AMA, LKM were evaluated from blood 
samples in patients receiving anti-TNFα inhibitor (adalimu mab, infliximab).
 Results:  Among 39 patients treated with anti-TNFα therapy, twenty of them 
developed ANA, mostly induced by infliximab. 55% ANA positive patients developed 
peripheral polyarthralgias with no need for intervention. No patients with positive 
autoantibodies developed a drug-induced lupus. The incidence of dsDNA, SMA and 
AMA was low and was not associated with autoimmune disease. 
Conclusions: Immune response induced by anti-TNFα is restricted to ANA, with 
lower prevalence of dsDNA antibodies, SMA and AMA. Further studies are needed to 
clarify the role of autoantibodies during anti-TNFα therapy. 
INTRODUCTIONBiological therapies including anti-tumor necrosis factor (TNF) alpha inhibitors are increasingly used for a rapidly 
expanding number of rheumatic and inflammatory bowel diseases (IBD). These agents have been studied extensively and 
have demonstrated acceptable efficacy and safety profiles [1-3]. The adverse effects of this treatment are infrequent, such as opportunistic, intracellular infections, especially reactivation of latent Mycobacterium tuberculosis, and an exacerbation 
of demyelinating disorders [4-6].  Autoimmune phenomena, ranging from asymptomatic laboratory changes to presence of 
systemic autoimmune diseases, were also reported [6-10]. Many studies, most of them conducted on populations 
of patients affected by rheumatoid arthritis, have confirmed 
induction of antinuclear antibodies (ANA) or double-stranded 
DNA autoantibodies (dsDNA) in patients treated with infliximab 
(IFX) [11,12]. Data on adalimumab (ADA) have shown lower 
rates, compared to IFX, of ANA and anti-dsDNA antibodies in 
both rheumatoid arthritis and Crohn’s Disease (CD) [2, 13]. No data have been published about the induction of auto-antibodies 
directed against smooth muscle (SMA), mitochondrial (AMA) and liver-kidney microsomal (LKM) antigens during treatment 
using tumor necrosis factor-α (TNFα) inhibitors. The stimulation 
mechanisms of its synthesis and role remain unclear. However, 
despite more than a decade using anti-TNFα agents, many questions remain. One of the most important is the association 
between autoantibody induction and certain diseases such 
as drug-induced lupus (DIL) with presence of arthritis, skin manifestations, and systemic symptoms. Post-marketing data 
on the two licensed anti-TNFα drugs have suggested an overall 
estimated incidence of DIL of 0.19-0.22% for IFX and 0.10% for 
ADA [8, 14]. 
The aim of this study was to report a “real life” clinical experience about the occurrence of these autoantibodies during 
12 months of observation in patients with IBD treated with ADA 
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or IFX. In addition, we attempted to correlate the appearance of 
autoantibodies with clinical manifestations discovered during the study.
METHODS
This study was performed in accordance with the principles 
of the Declaration of Helsinki, and its appendices, and with local 
and national laws. Approval was obtained from the hospital’s 
Internal Review Board and the Ethical Committee, and written informed consent from all patients.
Thirty-nine IBD patients eligible to anti-TNFα therapy were 
consecutively recruited into the study. Seventeen were treated 
with IFX (5 mg/kg IFX intravenously at weeks 0, 2, and 6, and 
every 8 weeks thereafter) and 22 were treated with ADA (160 
mg at week 0 and 80 mg at week 2; after induction treatment, 
the dose was 40 mg every 2 weeks via subcutaneous injection).
Treatment choice, according to European Crohn’s and Colitis 
Organization (ECCO) Guidelines was based on severity of disease, 
and on patient’s preference for the route of administration [15]. 
Medical records, including data about the presence of major extra intestinal manifestations, previous surgical procedures, the presence of familiar IBD, smoking habits and perianal 
involvement, were determined by a thorough review of the 
patient medical charts, which had been collected in uniform 
format. Previous and concomitant medical therapy was 
meticulously registered.  The patients were allowed to continue steroids and immunosuppressive drugs before and during anti-
TNFα treatment. No patient had an infectious disease, active or latent tuberculosis, neoplastic disease, heart failure, cytopenia 
or a demyelinating disorder. Follow-up appointments have been 
performed every 3 months with additional extraordinary visits 
if needed. These visits included clinical assessment, review of patient diaries and laboratory assessment (including C reactive 
protein). Levels of autoantibodies were determined at induction 
and after the one-year anti-TNFα period. 
Blood serum samples were collected from all patients at 
baseline and after 12 months of anti-TNFα treatment. The sera 
were stored at −80°C until testing. All the serum samples of 
IBD patients were analyzed in a single session according to the 
manufacturer’s instructions. ANA titers were measured by an 
indirect immunofluorescence (IFI) assay using HEp-2 cells as 
substrates according to the manufacturer’s guidelines. ANA 
titers ≥1:80 were considered clinically relevant and deﬁned as 
positive titers. Anti-dsDNA antibodies, both IgM and IgG, were analyzed by a semi quantitative Crithidia luciliae fluorescent test (CLIFT) according to the manufacturer’s guidelines (Inova 
Diagnostics Inc). DsDNA  values equal to or greater than 1:10 was 
interpreted as a positive result. ANA, ASMA, AMA, and anti-LKM 
were determined by indirect immunofluorescence (IFI) using 
slides of rat liver/kidney/stomach as antigen. We considered an 
antibodies titer ≥ 1:80 as positive result. 
At the time of auto-Ab testing, patients were interviewed for symptoms of autoimmune disorders (DIL, arthralgia, vasculitis, peripheral neuropathies, skin rash, and autoimmune hepatitis). 
DIL was defined as arthritis including joint swelling, serositis and 
positive antibodies requiring an immediate stop of anti-TNFα 
and initiation of steroids and/or immunosuppressive therapy 
(azathioprine, methotrexate) [16]. According to The Crohn’s & 
Colitis Foundation of America, we defined arthralgia as “aching 
or pain in the joints” in one or more joints [17].
STATISTICAL ANALYSIS
Statistical analysis was performed using Statistical Package 
for Social Science (SPSS) version 13.0 for Windows. Data were 
expressed as median or range. Continuous variables were 
analyzed by the Mann-Whitney test. A p value less than 0.05 was 
considered statistically significant.
RESULTS
Demographic data of patients are presented in table 1. 
We observed four ANA-positive (10.2%) patients before the 
beginning of anti-TNFα treatment (Table 2). In these cases, 
we found no change after 12 months of observation. After 12 
months of therapy, 20 patients (51.2%) developed a positive 
ANA titer; pattern was homogeneous in 13 cases. ANA induction 
was associated with de novo peripheral polyarthralgias in 11 
patients (55.0%); eight of these (72.7%) had concomitant 
immunosuppression. A single patient who developed positive 
ANA but not anti-dsDNA experienced polyarthralgia and a 
persistent skin rash, which led to discontinuation of IFX.
There were no dsDNA-positive patients at the beginning, 
but two cases (5.1%) of seroconversion was observed after 12 
months. These patients were also positive for ANA and developed polyarthralgias.
Five patients (12.8%) were SMA positive at baseline (Table 
2). On treatment, two of them remained positive (11.7%) while 
three became negative (17.6%); only one patient treated with 
ADA developed new SMA positivity (4.5%). These antibodies 
were not directed against actin and so they were not considered as a biologic marker of autoimmune liver disease. Indeed, none 
of the patients experienced alterations of liver function tests. All 
sera were negative at baseline for AMA antibodies; one induction 
(2.5%) was observed after 12 months of IFX treatment. During 
the whole study, we did not observe any anti-LKM positive patient.
DISCUSSION
Our data confirm that biological agents trigger the induction 
of ANA in an elevated number of IBD treated patients. The pathogenic mechanism that changes the humoral response leading 
to development of autoimmunity during anti-TNFα inhibitors 
therapy is unknown. Many hypothesis have been formulated 
concerning autoantibodies formation during anti-TNFα treatment. It could be hypothesized that release of intracellular 
nuclear substances, because of anti-TNFα-induced cytotoxicity, 
results in a humoral immune response [18]. Indeed, IFX has been 
shown to increase both the number of apoptotic T lymphocytes in the lamina propria and the number of apoptotic monocytes in 
peripheral blood in CD [19, 20]. Inhibitors of TNFα also lead to a decrease of C-reactive protein, promoting the clearance of cell debris resulting from apoptosis. The presence of cell debris leads 
to a prolonged stimulation of antibodies [12]. The other possible mechanisms that may result in autoantibodies production are the B-cell activation and production of autoantibodies through the 
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Table 1: Demographic and clinical data of IBD patients according to anti-TNFα agents received.
IFX
(n = 17)
ADA
(n = 22)
Age (years) 48 (34-62) 42 (21-65)
Male/Female 7 (41.1%)/10 (58.9) 10/12
CD/UC 9 (52.9)/8 (47.1) 22 (100%)/0
Age at presentation 41 (22-59) 35 (19-57)
Disease duration (months) 94 (29-260) 72 (12-230)
Refractoriness to immunosuppressant 9 (52.9) 5 (22.7)
Indication for anti-TNFα treatment   steroids dependent   steroids refractory   penetrating Crohn’s disease   extraintestinal manifestations
10 (58.8)
2 (11.7)
3 (17.8)
2 (11.7)
8 (36.4)
3 (13.6)
7 (31.8)
4 (18.2)
Immunosuppressant use ever/during anti-TNFα treatment 9 (52.9) 4 (18.2)
Data are given as median (range) or as number (%).
Abbreviations: IBD: Inflammatory Bowel Diseases; CD: Crohn’s Disease; UC: Ulcerative Colitis; IFX: Infliximab; ADA: Adalimumab.
Table 2: Frequency of autoantibodies in 39 patients treated with anti-TNFα.
At inclusion 12 months p value
(n = 39) IFX(n = 17)
ADA
(n = 22)
ANA ≥ 80 4 (10.2) 11 (64.7) 9 (40.0) ns
dsDNA ≥ 80 0 1 (5.9) 0 ns
SMA ≥ 80 5 (12.8) 0 1 (4.5) ns
AMA ≥ 80 0 1 (5.9) 0 ns
LKM ≥ 80 0 0 0 -Data as number (percentage).
Abbreviations: IBD: Inflammatory bowel diseases; TNFα: Tumor Necrosis Factor; IFX: Infliximab; ADA: Adalimumab; ANA: Antinuclear Antibodies; 
DsDNA: Double Strand DNA; SMA: Smooth Muscle Antibodies; AMA: Anti-Mitochondrial Antibodies; LKM: Liver-kidney Microsome.
up regulation of interleukin-10 [21] or an increase in Th2 activity 
[22].
Consistent with data reported in the literature, IFX seems to be the drug most closely related to the development of autoantibodies, probably because it is a chimeric antibody and 
this may cause a greater immune response. A possible mechanism leads through the binding of IFX to the transmembrane and 
soluble TNFα, rapidly lowering TNFα level and enhancing 
apoptotic cell death, which triggers the development of auto-Ab 
[23-25].
With regard to ADA, it specifically binds to soluble and 
transmembrane TNFα, but it is not known why it does not give rise to autoantibodies production as frequently as IFX does [26]. 
The observed rate of ANA induction (51.2%) in our cohort 
is consistent with data from the literature. On the contrary, 
the occurrence of anti-dsDNA (5.1%) is lower than that found 
previously [12,27-29]. Previous studies on the development of 
auto-Ab during anti-TNFα therapy in IBD patients have shown 
discrepant results. A French study showed ANA positivity in 14% 
of 35 CD patients before IFX treatment that increased to 53% 
after 12 months; dsDNA antibodies were detected in one patient 
(3%) at baseline and in 35% after 1 year of IFX treatment [27]. 
In another study [28], 22% of CD patients were ANA-positive 
at baseline and after 6 weeks of IFX treatment, an additional 
16.7% became ANA-positive; however, only three patients 
(8.3%) developed dsDNA antibodies. In another cohort of 125 
CD patients the cumulative ANA prevalence was 56.8% after a 
follow-up of 24 months, with 32.6% of dsDNA positivity [12]. In 
a study by Beigel et al.  44.4% of anti-TNFΑα treated IBD patients 
had elevated ANA titers, while 15.6% had dsDNA positivity. 
Among the subgroups (IFX, ADA, ADA after IFX, with and without 
immunosuppression, respectively) there was no statistically 
significant probability of developing ANA and dsDNA [29].  
Interestingly, 43% of our patients receiving concomitant 
immunosuppressive therapy were found to have an induction of 
ANA. This finding is consistent with some reports [12, 30] though the most recent study suggests a protective effect of concomitant 
immunomodulator both against ANA and DIL development 
[29]. Whereas these drugs have been shown to reduce the 
immunogenicity of anti-TNFα, our data suggest that azathioprine or methotrexate may have an additional or synergistic effect on the cell apoptotic process and the release of nuclear antigens. Only age seems related to the development of clinical signs of 
autoimmunity. Further, we can also speculate that in our cohort 
ANA induction correlated with older age and longer disease 
duration; we do not have enough data to correlate autoantidodies appearance during IFX therapy and female gender, as it have 
been recently reported [31].
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In spite of the appearance of ANA and anti-dsDNA positivity, 
no cases of DIL were observed. Reviewing the literature, DIL is 
generally rare among patients treated with anti-TNFα antagonists 
and most of the cases are reported in rheumatoid arthritis, while 
only a few reports exist for IBD patients [31,32]. 
Eleven out of 14 patients (78.6%) who developed arthralgia 
had ANA positivity, but anti-TNFα therapy could be continued 
without aggravation of symptoms, except in one patient who also 
developed a skin rash and was successfully treated with steroids 
after withdrawal from anti-TNFα therapy. We also searched 
for other auto-Ab, such as SMA and AMA that have poorly been 
thoroughly investigated in relation to anti-TNFα treatment until 
now. 
However, we are aware that this study has some limitations. First, because of the small number of patients data need to be 
confirmed in a larger series [33].  Secondly, follow up assessment of autoantibodies after drug discontinuation is not available 
because patients were refusal or drop-out.
Neverthless, our data confirm that despite the high frequency 
of auto-Ab development associated with anti-TNFα agents, 
relatively few patients develop autoimmune clinical symptoms. The strength of the present study, although the small sample size, 
is that we included a cohort of well-characterized IBD patients 
from high-quality referral center in Italy with standardized 
patient selection and follow-up. We believe that more extensive 
long-term studies are needed to clarify the influence of auto-Ab on clinical outcomes. 
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